P&G Hygiene FY26 net profit rises 35% to ₹857 crore on revenue growth
P&G Hygiene and Health Care posted a 35% rise in net profit to ₹857 crore for FY26, driven by revenue growth to ₹4,290 crore. The company expanded its net profit margin to 20% and recommended a final dividend of ₹60 per share. Key operational highlights include strong performance in Whisper and Vicks portfolios.

*this image is generated using AI for illustrative purposes only.
Procter & Gamble Hygiene and Health Care reported a net profit of ₹857 crore for the financial year ended March 31, 2026, an increase from ₹637 crore in the previous period. Revenue from operations rose to ₹4,290 crore, up from ₹3,374 crore in the prior year. The previous financial year (FY25) was a nine-month period due to the company’s shift in fiscal calendar, making direct year-on-year comparisons less precise.
The Board of Directors recommended a final dividend of ₹60 per equity share for FY26. This follows an interim dividend of ₹195 per share, which included a one-time special dividend of ₹25 per share, paid in February 2026. The aggregate dividend for the year amounts to ₹255 per share, subject to shareholder approval at the 62nd Annual General Meeting.
Financial Performance
The company’s profitability metrics showed significant improvement alongside top-line growth. Profit before tax stood at ₹1,167 crore, compared to ₹862 crore in the previous period. Earnings per share increased to ₹264 from ₹196 in the prior year.
| Metric: | FY26 | FY25 (9 Months) |
|---|---|---|
| Revenue From Operations: | ₹4,290 crore | ₹3,374 crore |
| Profit Before Tax: | ₹1,167 crore | ₹862 crore |
| Net Profit After Tax: | ₹857 crore | ₹637 crore |
| Dividend Per Share: | ₹255 | ₹175 |
What the Numbers Show
The improvement in net profit margin is notable. In FY26, the net profit margin expanded to approximately 20%, up from 19% in the previous nine-month period. This suggests that cost management or operational efficiencies may have contributed to bottom-line growth outpacing revenue growth. Additionally, the return on capital employed improved to 1.35 from 1.03, indicating better utilization of capital.
Operational Highlights
The company continued its focus on innovation across feminine care and healthcare portfolios. Key brands include Whisper and Vicks. The Whisper Period Panty portfolio and Vicks VapoRub were highlighted as strong performers. The company also launched Vicks Cough Syrup, targeting the herbal remedy segment, and upgraded Zzzquil Natura Sleep Gummies.
Corporate Governance
Several changes occurred in the board and management structure during the year. Mr. Gagan Sawhney stepped down as Non-Executive Director in October 2025. Ms. Mrinalini Srinivasan ceased to be Chief Financial Officer in June 2025, succeeded by Mr. Gaurav Bhartia. Post-closure of the financial year, Ms. Srividya Srinivasan was appointed as Whole-time Director and CFO effective July 1, 2026.
The 62nd Annual General Meeting will be held on September 8, 2026, via video conference. Shareholders will vote on the re-appointment of Mr. Pramod Agarwal and the appointment of Ms. Srividya Srinivasan.
Historical Stock Returns for P&G Hygiene and Health Care
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.73% | -1.55% | -5.77% | -27.70% | -36.95% | -34.78% |
How will the new CFO, Ms. Srividya Srinivasan, plan to sustain the improved return on capital employed of 1.35 in the upcoming fiscal year?
What is the projected market penetration strategy for the newly launched Vicks Cough Syrup in the competitive herbal remedy segment?
Will the shift to a full 12-month fiscal calendar in FY26 provide a clearer baseline for assessing the sustainability of the 20% net profit margin expansion?


































